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Abstract
Vidhi Thakkar and Terrence Sullivan have done a careful and thought-provoking job in trying to establish comparable 
estimates of public spending on health services and policy research (HSPR) in Canada, the United Kingdom and the 
United States. Their main recommendation is a call for an international collaboration to develop common terms and 
categories of HSPR. This paper raises two additional questions that have an international comparative dimension: 
There is little doubt that public spending on HSPR represents more than the “tip of the iceberg,” but how much 
more? And how do the countries fare on the uptake of HSPR by decision-makers? I have long speculated that 
probably as much or more is spent by provincial/territorial governments, regional health authorities, hospitals and 
other agencies on HSPR activities carried out by consultants in Canada than by the federal, provincial/territorial 
granting agencies. Support for this contention is provided in a paper by Penno and Gauld on spending on external 
consultancies by New Zealand’s District Health Boards (DHBs). Their estimate of the amount spent on consultancies 
in 2014/15 represents 80% of the amount spent on research by the Health Research Council of New Zealand in 2015. 
In terms of the uptake of research Jonathan Lomas pioneered the concept of linking researchers with decision-
makers when he became the founding Chief Executive Officer  (CEO) of the Canadian Health Services Research 
Foundation (CHSRF) in 1997. An early assessment was promising, and it would be interesting to know if other 
countries have tried this. Most assessments of research uptake and impact are short-term in nature. It might be 
insightful to assess HSPR developments over the long term, such as prospective reimbursement through diagnosis 
related groups (DRGs) that has been evolving internationally for more 40+ years. In the short term the prospects for 
a major infusion of funding in HSPR in Canada are not promising, although there have been welcome investments 
in the Canadian Foundation for Healthcare Improvement (formerly CHSRF).
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Vidhi Thakkar and Terrence Sullivan have done a careful and thought-provoking job in trying to establish comparable estimates of public spending 
on health services and policy research (HSPR) in Canada, 
the United Kingdom, and the United States. They have put 
forward two calls for action. First, they emphasize the need 
to assess the impact of increased investment in HSPR on 
health system performance and quality of care. Second, 
they recommend an international collaboration to develop 
common terms and categories of HSPR.1
This paper raises two additional questions that have an 
international comparative dimension:
•	 There is little doubt that public spending on HSPR 
represents more than the “tip of the iceberg,” but how 
much more? And
•	 How do the countries fare on the uptake of HSPR by 
decision-makers?
It is important to recognize that HSPR is a wide field of 
endeavour. The Canadian Institutes of Health Research 
(CIHR) defines it as “a multidisciplinary field of scientific 
investigation that studies how social factors, financing 
systems, organizational structures and processes, health 
technologies, and personal behaviours affect access to 
healthcare, the quality and cost of healthcare, and ultimately, 
Canadians’ health and well-being.”2
How Much More Spending Is There on HSPR Than Public 
Spending?
As someone who has been an observer of the HSPR scene in 
Canada for almost 40 years, and an active peer reviewer for 
several HSPR granting bodies, I have long speculated that 
probably as much or more is spent by provincial/territorial 
governments, regional health authorities, hospitals and other 
agencies on HSPR activities carried out by consultants in 
Canada than by the federal, provincial/territorial granting 
agencies. Supporting evidence for this contention is provided 
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in a recent paper by Penno and Gauld on spending on 
external consultancies by New Zealand’s District Health 
Boards (DHBs). In 2016 they submitted Official Information 
Act requests to each of New Zealand’s 20 DHBs requesting 
details on all external consultancies over the 3-year period 
from 2012/2013 to February 2016, which they subsequently 
refined to just those costing more than NZ$ 10 000. Thirteen 
DHBs agreed to provide the information, one gave them 
no response, four refused and two would only provide it at 
a significant cost. They supplemented the information with 
figures provided by the DHBs to the government Health 
Select Committee. In 2014/2015 they estimated the total 
expenditure at NZ$ 6 4128 553.3
How does this compare with public expenditure? According 
to the 2016 annual report of the Health Research Council 
of New Zealand, in 2015 research grant costs amounted to 
NZ$ 80 960 million; hence the consultancy expenditures 
represented almost 80% of the public total.4 To be fair this 
is a rough comparison. As veteran healthcare consultant 
Neil Stuart has pointed out, consulting expenditures on 
information technology and administrative systems should 
not be included. What would be reasonable to include as 
HSPR spending would be items including strategy consulting, 
planning, surveys, stakeholder engagement/consultation, 
quality improvement and evaluations (N. Stuart, personal 
communication, August 2017). Hunter and Frank make a 
similar point in their commentary, noting that the English 
National Health Service commissions applied HSPR from 
academics.5
It would be no easy task to identify consultancy expenditures 
for HSPR in Canada. In the case of hospitals, the Management 
Information System Standards used by the Canadian Institute 
for Health Information include secondary accounts for 
“management fees” and “professional fees not elsewhere 
classified.”6 However this would include a mixture of the 
items categorized by Stuart as well as items such as legal fees. 
In 2010 the Auditor General of Ontario released a special 
report on the use of consultants in selected organizations. It 
contained three recommendations intended to improve the 
reporting on the procurement and management processes 
with consultant use generally.7 Suffice it to say that few would 
argue that public non-granting agency spending on HSPR 
activities is trivial, and moreover one might venture that 
fewer results come into the public domain as compared to the 
output of public agency-funded research.
Another important category of public spending on HSPR 
activities is that of research funded by commissions and 
task forces, which have been very popular in Canada. A key 
example is the extensive external research program of the 
2001-2002 Royal Commission on the Future of Health Care in 
Canada, led by Roy Romanow. It commissioned 40 discussion 
papers from experts from across Canada and internationally, 
as well as 3 major research projects.8
How Do Countries Fare on the Uptake of HSPR?
In 1997 McMaster University professor Jonathan Lomas 
produced an influential working paper that examined the 
challenges and prospects of moving research into decision-
making in the health sector, which he referred to as getting 
“beyond the sound of one hand clapping.”9 Lomas suggested 
that a key reason for the lack of uptake of research was that 
researchers and decision-makers were working independently 
of each other; “it is like two people trying to assemble a jigsaw 
puzzle, each with half of the pieces…but each working in a 
separate room.”9 He added that a further problem was that 
both researchers and decision-makers failed to recognize 
that research and decision-making are not discrete events, 
but rather iterative processes, and he proposed that both 
parties should have more opportunities to engage in exchange 
throughout their processes. Another major contribution 
of the paper was that Lomas developed a categorization of 
the different types of decision-maker, including clinical, 
legislative, administrative and industry decision-makers.
Lomas had an opportunity to put these ideas into action when 
he became the founding Chief Executive Officer (CEO) of the 
Canadian Health Services Research Foundation (CHSRF). 
The CHSRF was established through an initial endowment 
of $65 million in the 1996 federal budget. As described in 
the budget, the purpose of the fund was to “bring together 
partners from provincial governments, health institutions and 
the private sector…the research will be practical in nature…
By jointly setting priorities and pooling efforts, the results of 
the research should be more readily and widely adopted to the 
benefit of all Canadians.”10
Lomas introduced two innovations in the CHSRF granting 
process. First, all researchers were required to have a decision-
maker partner. Second, grant proposals were adjudicated 
based on an equal weighting of scientific merit and potential 
impact, and the review panels comprised researchers and 
decision-makers representing the different types. An early 
evaluation of the CHSRF experience by Ross et al reported 
that on balance, both researchers and decision-makers felt 
it was a beneficial experience. The researchers reported 
benefits including a greater focus on application, access to 
data sources and a greater understanding of the decision-
making environment. Decision-makers reported that their 
involvement had made them more reflective about their 
activities.11 It would be interesting to know how successful 
similar initiatives in the United States and United Kingdom 
have been in improving the relevance and uptake of HSPR. 
The United States, for example has Academy Health, which 
was established in 2000 and acts as a broker of information 
between health services researchers, policy decision-makers 
and practitioners.12
The CIHR has just launched a new program of Health System 
Impact Fellowships that will embed post-doctoral Fellows in 
health service organizations and it will be interesting what 
impact this has on both researchers and decision-makers.13
With regard to Thakkar and Sullivan’s proposed international 
collaboration, while this is certainly a good idea, I would suggest 
that “charity begins at home.” In 1998, Lewis and colleagues 
put forward an idea for an “evidence-based decision-making 
trade show” that would bring together governors, providers, 
managers, policy-makers and industry with the community 
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of healthcare researchers in academic and non-academic 
settings from across Canada. The authors postulated that this 
would offer several advantages such as permitting a state-of 
the-art exchange of needs, products, strategies, replicable 
successes and pitfalls to avoid.14 Such a trade show has yet to 
occur. Researchers, clinicians and healthcare administrators 
largely attend their own conferences, and probably mainly at 
the provincial level.
Returning to the concept of international collaboration this 
is something where the consulting industry could help. The 
large consulting firms operate in numerous countries and 
one would imagine that they share methods, findings and 
key lessons across them. For example, KPMG’s Mark Britnell 
developed a comparative 25-country study In Search of the 
Perfect Health System based on his experience of working in 
60 countries. He concluded that there is no perfect health 
system, but if there was, it might be based on 12 qualities 
from the best country experience for each, such as the values 
and universal coverage of the UK and the research and 
development of the United States.15
Prospects for a Big Boost in Funding for HSPR
In their conclusion Thakkar and Sullivan suggest that it 
might be useful to set a target for HSPR funding, as was 
done in England in the 1990s. Tamblyn et al have suggested 
that whereas knowledge-intensive industries invest 5% (of 
their budgets) in research and development an appropriate 
investment in HSPR for Canada in 2014 would have been 
$11 billion (based on total health spending of $215 billion).16 
Considering that CIHR’s total research budget is roughly $1 
billion this would clearly be a tall order.17 One of the challenges 
in securing funding for health research in general and HSPR 
specifically is the need to demonstrate return-on-investment. 
An added challenge continues to be the issue identified 
by Lomas in 1997 of the failure to appreciate research and 
decision-making as a process rather than as a discrete event. 
This results in a short-term focus on evaluation thus making 
it difficult to demonstrate significant impacts. In this regard it 
might be helpful to cultivate a longer-term view of the impact 
of HSPR. A case in point would be what I would consider 
to be the most successful HSPR story ever, and that is the 
adoption of prospective reimbursement by diagnosis related 
groups (DRGs) that began with research conducted by Fetter 
and Thompson at Yale University in the 1970s.18 DRGs were 
initially designed as a means of monitoring utilization of 
resources and quality of care, but were adopted by the State 
of New Jersey in 1978 as a prospective payment mechanism 
and nationally by the US Medicare program in 1983.19 DRGs 
are now widely used internationally,20 and the Centers for 
Medicare and Medicaid Services is extending the concept 
further with “bundled payments”; prospective payment that 
cover all health services for an episode of care, including 
hospital care, physician care home care and rehabilitation.21 
Canada developed its own version of DRGs – Case Mix 
Groups in the 1980s but it is only in the last decade that some 
provinces have started to adopt them as a funding tool.22 
DRGs are no panacea to be sure but they are an excellent case 
study of the uptake of research.
In the short-to-medium term the prospects of a major 
infusion of resources into HSPR do not appear promising. In 
2015 the Advisory Panel on Healthcare Innovation, chaired 
by David Naylor, recommended a Healthcare Innovation Fund 
that would ramp up to $1 billion annually by 2020 that would 
support initiatives related to HSPR23 but to date there has been 
no major commitment by the federal government, aside from 
new investments in the Canadian Foundation for Healthcare 
Improvement (formerly CHSRF) (CFHI) totaling $90 million 
in the 2016 and 2017 federal budgets plus ongoing annual 
funding of $17 million.24 CFHI has been doing unique work 
in Canada to promote the spread and scale-up of innovative 
models of care. In 2014-2015 it funded 19 teams across 
Canada to implement the INSPIRED care model for chronic 
obstructive pulmonary disease and is now in the competitive 
process of scaling up some of these sites to six health regions 
or jurisdictions (eg, province).25
Most recently the report of Canada’s Fundamental Science 
Review, also chaired by Naylor, has recommended an 
investment of $485 million over four years to fund 
investigator-led research, although this would be allocated 
across the federal granting councils.26 Science Minister Kirsty 
Duncan welcomed the report’s April, 2017 release, but it will 
remain to be seen in the 2018 federal budget if it will result in 
a significant investment.27
Conclusion
In conclusion – there is little comfort in the July, 2017 release 
of the Commonwealth Fund’s 11-country comparative study. 
The findings show that Canada has traded places with France 
to move up to occupy ninth place; on the five individual 
dimensions that make up the composite score, Canada ranks 
no better than sixth.28 There seems little doubt that greater 
investment in HSPR would help the situation, but linkages 
need to be stronger between researchers and decision-makers, 
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